We are live on ! Find out more
ES

Enavate Sciences Portfolio holdings

AUM $345M
1-Year Est. Return 134.64%
This Fund
S&P 500
This Quarter Est. Return
+6.06%
1 Year Est. Return
+134.64%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$345M
AUM Growth
-$6.13M
Cap. Flow
-$3.3M
Cap. Flow %
-0.96%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CAMP icon
CAMP4 Therapeutics
CAMP
+$3.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SION
1
Sionna Therapeutics
SION
$311M
$109M 31.56%
2,478,030
– –
ZBIO
2
Zenas BioPharma
ZBIO
$2.08B
$99.5M 28.8%
3,919,159
– –
IMNM icon
3
Immunome
IMNM
$2.72B
$76.6M 22.17%
3,613,799
– –
BBOT
4
BridgeBio Oncology
BBOT
$391M
$20M 5.8%
2,626,946
– –
CMPX icon
5
Compass Therapeutics
CMPX
$333M
$17.1M 4.94%
7,788,150
– –
UPB
6
Upstream Bio Inc
UPB
$300M
$17M 4.93%
2,459,703
– –
CAMP icon
7
CAMP4 Therapeutics
CAMP
$263M
$6.23M 1.8%
1,425,541
-765,379
-35% -$3.3M

Similar funds

LCM
Lonestar Capital Management San Francisco, California $345M AUM 80.24% 1-Year Est. Return
M2MC
Matthew 25 Management Corp Ambler, Pennsylvania $345M AUM 31.27% 1-Year Est. Return
FRA
Front Row Advisors Tiburon, California $345M AUM 39.04% 1-Year Est. Return
MC
Muhlenkamp & Co Wexford, Pennsylvania $345M AUM 34.25% 1-Year Est. Return
BMC
Bear Mountain Capital Seattle, Washington $345M AUM 13.71% 1-Year Est. Return
GSC
G&S Capital Denver, Colorado $345M AUM 32.53% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $346M AUM 31.14% 1-Year Est. Return
WFI
West Family Investments Carlsbad, California $345M AUM 46.29% 1-Year Est. Return

Enavate Sciences's Q2 2026 Portfolio in Review

As of Q2 2026, Enavate Sciences held 7 positions worth $345M, down 1.7% from $352M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2026: portfolio turnover was 0%. Enavate Sciences opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Enavate Sciences's biggest Q2 2026 reduction was CAMP4 Therapeutics, cutting an estimated $3.3M.
  • Enavate Sciences's ten largest holdings make up 100% of its $345M portfolio in Q2 2026.
  • Enavate Sciences opened 0 new positions and closed 0 in Q2 2026.
  • Enavate Sciences's portfolio value fell 1.7% quarter-over-quarter to $345M.

Based on Enavate Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.